Your Navigation:PCAR > Abstract
Search pcar
Pharmaceutical Care and Research: 2019; 19(1):76-78
DOI: 10.5428/pcar20190119
Analysis of one case of suspected interstitial lung disease induced by pazopanib in treatment of renal sarcomatoid cell carcinoma
1. BAI Rong(a
2. MA Yabin(a )
3. ZHAI Xiaobo(a )
4. et al(a )
Welcome to PCAR! You are the number 292 reader of this article!
Please cite this article as:
BAI Rong,MA Yabin,ZHAI Xiaobo,et al,. Analysis of one case of suspected interstitial lung disease induced by pazopanib in treatment of renal sarcomatoid cell carcinoma[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(1): 76-78.
1. QI Haofei,CHEN Ligong,LIU Bingni,et al.Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents[J].Bioorg Med Chem Lett,2014,24(4):1108-1110.
2. Sternberg C N,Davis I D,Mardiak J,et al.Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase Ⅲ trial[J].J Clin Oncol,2010,28(6):1061-1068.
3. van der Graaf W T,Blay J Y,Chawla S P,et al.Pazopanib for metastatic soft-tissue sarcoma (PALETTE):a randomized,double-blind,placebo-controlled phase 3 trial[J].Lancet,2012,379(9829):1879-1886.
4. Schutz F A,Choueiri T K,Sternberg C N.Pazopanib: clinical development of a potent anti-angiogenic drug[J].Crit Rev Oncol Hematol,2011,77(3):163-171.
5. Abramson R G,Abramson V G,Chan E,et al.Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms[J].AJR Am J Roentgenol,2013,200(3):475-483.
6. Ide S,Sakamoto N,Hara S,et al.Interstitial lung disease induced by pazopanib treatment[J].Intern Med,2017,56(1):79-83.
7. Jules-Elysee K,White D A.Bleomycin-induced pulmonary toxicity[J].Clin Chest Med,1990,11(1):1-20.
8. Miettinen P J,Warburton D,Bu D,et al.Impaired lung branching morphogenesis in the absence of functional EGF receptor[J].Dev Biol,1997,186(2):224-236.
9. Ishiguro Y,Ishiguro H,Miyamoto H.Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia[J].Oncotarget,2013,4(4):550-559.
10. GAO Xuan,LI Zhiping.Gefitinib-induced interstitial lung disease:prevention and treatment[J].Adv Drug React J,2011,13(3):165-168.In Chinese with English abstract.
11. Seto T,Seki N,Uematsu K,et al.Gefitinib-induced lung injury successfully treated with high-dose corticosteroids[J].Respirology,2006,11(1):113-116.
12. Tabata C,Tabata R,Kadokawa Y,et al.Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice[J].J Immunol,2007,179(1):708-714.
13. Lechtzin N,Hilliard M E,Horton M R.Validation of the cough quality-of-life questionnaire in patients with idiopathic pulmonary fibrosis[J].Chest,2013,143(6):1745-1749.
14. YANG Weilin,ZHANG Lin,ZHANG Wanggang,et al.Analysis of 38 cases of elderly patients with pulmonary interstitial fibrosis treated by thalidomide[J].Shaanxi Med J,2011,40(1):91-93.In Chinese.
15. Ohnishi K,Sakai F,Kudoh S,et al.Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate[J].Leukemia,2006,20(6):1162-1164.
16. Bergeron A,Réa D,Levy V,et al.Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series[J].Am J Respir Crit Care Med,2007,176(8):814-818.
17. Bugés C,Carcereny E,Moran T,et al.Interstitial lung disease arising from erlotinib treatment in a Caucasian patient[J].Clin Lung Cancer,2015,16(2):e1-e3.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330